Dr. Aditya K. Samal, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 286
Licensed in Texas since 2002, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
TX license L5122 (first issued 2002; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Houston Methodist Willowbrook Hospital Houston, TX
Medical groups
- Cardiovascular Specialists of Willowbrook PLLC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 286
- Services billed
- 2,433
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 303 | 265 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 269 | 37 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 253 | 238 |
| Established patient office or other outpatient visit, 20-29 minutes | 249 | 106 |
| Established patient office or other outpatient visit, 30-39 minutes | 192 | 140 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 165 | 64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 160 | 127 |
| Injection, regadenoson, 0.1 mg | 76 | 18 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 63 | 18 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 62 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Houston, TX | 300 |
| Atorvastatin Calcium Other prescribers in Houston, TX | 220 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Houston, TX | 187 |
| Amlodipine Besylate Other prescribers in Houston, TX | 147 |
| Furosemide Other prescribers in Houston, TX | 146 |
| Nifedipine Er (nifedipine) Other prescribers in Houston, TX | 140 |
| Xarelto (rivaroxaban) Other prescribers in Houston, TX | 134 |
| Carvedilol Other prescribers in Houston, TX | 121 |
| Metoprolol Succinate Other prescribers in Houston, TX | 121 |
| Metoprolol Tartrate Other prescribers in Houston, TX | 105 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 53 payments worth $1,367 in total to this clinician.
| Abbott Laboratories | $384 |
|---|---|
| Novartis Pharmaceuticals Corporation | $198 |
| Boston Scientific Corporation | $160 |
| Merck Sharp & Dohme LLC | $121 |
| Actelion Pharmaceuticals US, Inc. | $102 |
| Bard Peripheral Vascular, Inc. | $97.07 |
| E.r. Squibb & Sons, L.l.c. | $55.66 |
| Bridgebio Pharma, Inc. | $48.56 |
| Food and Beverage | $1,367 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $708,305 in research payments for these studies, mostly to the institutions running them.
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or O…
Amgen Inc. - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - Study name not reported
Novo Nordisk As - A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Eli Lilly and Company · Recruiting · NCT07269210
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.